Gilead Halts 6 Zydelig Trials as FDA, EMA Warn of Deaths From Respiratory Infections 

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

FDA is alerting health care professionals about reports of an increased rate of adverse events, including deaths, in clinical trials with the cancer medicine Zydelig (idelalisib) in combination with other cancer medicines.

To access this subscriber-only content please log in or renew your subscription.

Looking for IP Login? Our IP Login system is now automatic. If your institution has a site license, please log in from on site or via your VPN to access this content.

Login Subscribe

YOU MAY BE INTERESTED IN

Login